Genmab sees strong performance for Darzalex

Sunday 27 November 2022


Genmab A/S of Denmark has revised upward its guidance for revenue and operating profit for 2022 following a strong performance of Darzalex (daratumumab), a monoclonal antibody therapy for multiple myeloma that is licensed to Janssen Biotech Inc. Genmab receives royalties on Darzalex sales which represent a significant proportion of group revenue. The company also receives royalties from Horizon Therapeutics Plc for Tepezza, a medicine for thyroid eye disease, and for Kesimpta (ofatumumab) for multiple sclerosis from Novartis.